Under the accelerated fundraising and expansion of pharmaceutical equipment leading enterprises, the market competitiveness will continue to improve

【Pharmaceutical network market analysis】Pharmaceutical equipment is one of the basic facilities of Pharmaceutical enterprises in China, in recent years, due to favorable policies, expanding market demand, accelerated transformation of the pharmaceutical industry and other factors, China's pharmaceutical equipment industry has also ushered in a good opportunity
for development.

It is worth noting that while the scale of the pharmaceutical equipment market is growing, many pharmaceutical machinery companies, especially the head enterprises, are still accelerating the expansion of fundraising
.

Under the accelerated fundraising and expansion of pharmaceutical machinery enterprises, the market competitiveness will continue to improve (picture source: pharmaceutical network) For example, Dongfulong recently released a prospectus
for the issuance of A-share shares to specific targets in 2022.

According to the announcement, the total amount of funds raised by the issuance of shares to specific targets does not exceed 3.
2 billion yuan (including this number), and after deducting the issuance fee, it is intended to be used to invest in the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, the life science industrialization base project of Zhejiang Dongfulong Biotechnology Co.
, Ltd.
and supplementary working capital
.

It is understood that as early as February 28, Dongfulong disclosed that it intends to raise no more than 3.
2 billion yuan for a number of biomedical equipment industrialization projects
.

Prior to this, Dongfulong Intelligent Equipment Manufacturing (Jiangsu) Co.
, Ltd.
, a wholly-owned subsidiary of Dongfulong, has also obtained the "Jiangsu Investment Project Filing Certificate"
issued by the Administrative Examination and Approval Bureau of Dongtai City, Jiangsu Province.

On August 2, Chutian Technology issued an announcement that the company intends to jointly fund the establishment of a company engaged in providing precision manufacturing and molds for medical equipment, medical equipment, mechanical engineering and other related precision manufacturing and molds in Changsha Ningxiang City, Hunan Province
.

The name of the joint venture company is Chutian Changxing Precision Manufacturing (Changsha) Co.
, Ltd.
(hereinafter referred to as "Chutian Changxing"), with a registered capital of 50 million yuan
.

After the establishment of the joint venture company, the company subscribed to contribute 25.
5 million yuan, accounting for 51% of its equity, and is a holding subsidiary
of the company.

In April, Canaan Technology also announced that it intends to invest 50 million yuan in its own funds to establish a wholly-owned subsidiary, Tianjin Canaan Biomedical Equipment Co.
, Ltd.
(hereinafter referred to as "Tianjin Canaan").


The announcement shows that this foreign investment is an important part of the company's extension of the biopharmaceutical equipment industry chain, which is conducive to the horizontal expansion of the company's biological pharmaceutical equipment, enhancing the company's market competitiveness and sustained profitability, and is of great strategic significance to the company's improvement and strengthening of the layout of biopharmaceutical equipment, which is in line with the long-term development strategy
of all shareholders and the company.

It is worth mentioning that in 2020, Canaan Technology also plans to raise no more than 450 million yuan of funds for the construction of intelligent logistics system production center, the construction project of pharmaceutical liquid distribution system production center, the upgrading and expansion project of pharmaceutical research and development service platform, the construction project of HEADQUARTERS base, and the supplementary working capital
.

The industry believes that at present, major enterprises are raising funds to expand production, which means that in the current changing pharmaceutical environment, the development goal of domestic pharmaceutical machinery companies is not simply to pursue profits, but to find more new sustainable growth points in the industry by continuously expanding business, increasing new additions, and creating new projects
.

This includes both products and services and internationalization
.

In the future, under the background of pharmaceutical machinery enterprises constantly exploring clear industry development trends and new needs of market users, basing on a new starting point, formulating new plans, continuous rock climbing, and accelerating transformation and upgrading, the company's own market competitiveness is expected to continue to improve while import substitution may be further accelerated
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.